Related by context. All words. (Click for frequent words.) 84 Phase 2b Clinical Trial 82 Phase IIb Trial 81 Phase III Clinical Trial 81 Study Evaluating 81 Phase 2b Trial 81 Phase IIb Clinical Trial 81 Clinical Trial Results 80 Phase 2a Trial 80 Dose Ranging Study 79 Phase 2a Clinical Trial 79 Phase III Trial 79 Preclinical Data 79 Meets Primary Endpoint 79 Drug Candidate 79 Patients Treated With 79 Previously Treated 79 Metastatic Melanoma 78 Oral Fingolimod 78 Well Tolerated 78 Phase 2b Study 78 Preclinical Study 78 Completes Enrollment 78 Pivotal Study 77 Receives Orphan Drug Designation 77 Improves Survival 77 Trial Evaluating 77 Initiate Phase 77 Clinical Trial Evaluating 77 Long Term Efficacy 77 Prolongs Survival 77 Completes Patient Enrollment 77 Relapsing Multiple Sclerosis 77 Pharmacokinetic Study 77 Pivotal Phase III 76 Controlled Study 76 Antitumor Activity 76 Phase IIa Clinical Trial 76 Pivotal Trial 76 Patient Enrollment 76 Randomized Phase 76 Newly Diagnosed Multiple Myeloma 76 Metastatic Prostate Cancer 76 Monotherapy 76 Pooled Analysis 76 Phase III Trials 76 Relapsed Multiple Myeloma 76 Novel Oral 76 Adjuvant Treatment 75 Anti Tumor Activity 75 Dose Escalation 75 Single Dose 75 Combination Treatment 75 Patients Treated 75 Elderly Patients 75 Double Blind Placebo 75 Demonstrates Positive 75 Randomized Clinical Trial 75 Presents Positive 75 Controlled Trial 75 Heart Failure Patients 75 Is Well Tolerated 75 Presents Preclinical Data 75 First Patient Dosed 75 Combination REOLYSIN R 75 Patients Suffering 74 Adjuvant Therapy 74 Prospective Randomized 74 Pivotal Phase 74 Hsp# Inhibitor 74 Advanced Melanoma 74 Pivotal Clinical Trial 74 Adjunctive Therapy 74 Placebo Controlled Trial 74 Study Showed 74 Demonstrates Significant 74 Chronic Hepatitis C 74 Investigational Agent 74 Phase 1b Clinical Trial 74 Renal Cell Carcinoma 74 Randomized Phase II 74 Investigational Compound 74 Randomized Double Blind Placebo 74 Severe Sepsis 74 Initiates Clinical Trial 74 FDA Approvals 73 Improves Outcomes 73 Cutaneous T 73 Diabetic Patients 73 First Patient Enrolled 73 Survival Benefit 73 IND Application 73 Relapsed Refractory 73 Advanced Renal Cell 73 Clinical Study 73 Present Preclinical Data 73 Previously Untreated 73 Hypertensive Patients 73 Patients Undergoing 73 Metastatic Renal Cell Carcinoma 73 Humanized Anti 73 JAK Inhibitor 73 Novel Antibiotic 73 Statistically Significant 73 Platelet Inhibition 73 Topline Results 73 Phase Ib Clinical Trial 73 Subgroup Analysis 73 Knee Osteoarthritis 73 Lung Cancer Trial 73 IN PATIENTS WITH 73 Randomized Double Blind 73 Tezampanel 73 Complicated Skin 73 Randomized Study 73 Antiviral Activity 73 Shows Promising 72 Relapsing Remitting Multiple Sclerosis 72 NDA Submission 72 Investigational Treatment 72 Clinical Trial Data 72 FDA APPROVES 72 Myeloma Patients 72 Treatment Naïve 72 Initiates Phase II 72 Statin Therapy 72 Rheumatoid Arthritis Patients 72 Dose Escalation Study 72 Pivotal Trials 72 Hormone Refractory Prostate Cancer 72 Unfractionated Heparin 72 Appears Safe 72 Randomized Double blind 72 Granted Orphan Drug 72 Plus Ribavirin 72 Initiates Phase 72 Node Positive 72 Neuroprotective Effects 72 Acute Ischemic Stroke 72 Initiate Clinical Trial 72 IND Filing 72 Randomized Controlled 72 Sapacitabine 72 Clinical Efficacy 72 HCV Protease Inhibitor 72 Treatment Resistant 72 Infected Patients 72 Improve Survival 72 Clinical Outcome 72 IIa Clinical Trial 72 Novel Inhibitor 72 Disease Progression 72 Pharmacokinetics PK 72 Phase III Clinical Trials 72 Kinase Inhibitor 72 Placebo Controlled 71 Demonstrates Efficacy 71 dependent kinase inhibitor 71 Kidney Transplant Patients 71 FDA Accepts 71 Improved Survival 71 Mouse Model 71 HDAC Inhibitor 71 Adjuvant Chemotherapy 71 Pulmonary Arterial Hypertension 71 Successfully Completes Phase 71 Patients Enrolled 71 Refractory Hodgkin Lymphoma 71 Castration Resistant Prostate Cancer 71 Anti Tumor 71 Confirmatory Phase 71 Vaccine Adjuvant 71 Multicenter Randomized Double 71 Slow Progression 71 Submits NDA 71 Solid Tumors 71 Mylan Receives Approval 71 Demonstrates Potent 71 Autologous Stem Cell Transplantation 71 Safinamide 71 TO AVOID PREGNANCY WHILE 71 Vicriviroc 71 Patients Receiving 71 Metabolic Efficiency 71 Advanced Prostate Cancer 71 Fungal Infections 71 Metastatic Colorectal Cancer 71 Stent Implantation 71 Polymerase Inhibitor 71 Stent Restenosis 71 Renal Impairment 71 Overactive Bladder 71 Files IND 71 Chronic Myeloid Leukemia 71 By JENNIFER LEARN 71 PEGylated Fab fragment 71 JAK2 Inhibitor 71 Tolerability 71 oral prodrug 71 Initiate Phase III 71 Randomized Controlled Trial 71 Drug Shows Promise 71 Aurora Kinase 71 Pediatric Patients 71 Late Breaker 71 Interferon Beta 71 Dose Finding 71 Prostate Cancer Patients 71 Brentuximab Vedotin SGN 71 FOLOTYN ® 71 Investigational Oral 71 Treatment Naive Patients 71 Initiates Phase III 71 Recombinant Human 71 Receptor Agonist 71 pralatrexate injection folate analogue 71 Meta Analysis 71 Phase III Pivotal 71 Unresectable 71 Personalized Immunotherapy 71 Effectively Treats 71 Shows Efficacy 71 Tyrosine Kinase Inhibitor 71 Hepatocellular Carcinoma 70 Gout Drug 70 familial amyloidotic polyneuropathy FAP 70 Benign Prostatic Hyperplasia 70 Fewer Side Effects 70 Phase III Pivotal Trial 70 Therapeutic Efficacy 70 Clinical Evaluation 70 Hormone Receptor Positive 70 Aflibercept 70 Initiates Enrollment 70 Romidepsin 70 Fast Track Status 70 Acute Myocardial Infarction 70 Myelodysplastic Syndromes 70 fosbretabulin 70 Microplasmin 70 Patient Enrolment 70 Protease Inhibitor 70 Sustained Efficacy 70 Lupus Nephritis 70 Clinical Trial 70 Cholesterol Lowering Drug 70 Placebo Controlled Study 70 Chemoradiation 70 Investigational Drug 70 Collaborators Present 70 Bare Metal Stents 70 Efficacy Trial 70 Treatment Experienced 70 Peginterferon 70 Orally Active 70 Diabetic Nephropathy 70 Inhaled Corticosteroids 70 Liver Metastases 70 Disease Modifying 70 HER2 Positive Breast Cancer 70 Postmenopausal Women 70 Glufosfamide 70 Liver Failure 70 Resistant Hypertension 70 Dual Antiplatelet Therapy 70 R roscovitine CDK cyclin 70 Potent Antiviral Activity 70 Prostate Cancer Vaccine 70 MEK Inhibitor 70 R lenalidomide 70 alfa 2a 70 Versus Placebo 70 Combination Therapy 70 Significantly Improved 70 Proves Effective 70 Gene Therapy Trial 70 Malignant Melanoma 70 Nebulized 70 Initiated Phase 70 Preclinical Efficacy 70 Prospective Randomized Trial 70 Presents Preclinical 70 HER2 Positive 70 Ranolazine 70 Radical Prostatectomy 70 Anticancer Activity 70 Antigen Specific 70 Blind Placebo Controlled Trial 70 dasatinib Sprycel ® 70 Study Demonstrates 69 Anti Inflammatory Drug 69 Glatiramer Acetate 69 KRN# 69 Parathyroid Hormone 69 Universal Flu Vaccine 69 Advanced Colorectal Cancer 69 See CLINICAL PHARMACOLOGY 69 Chronic Lymphocytic Leukemia 69 Spectrum Pharmaceuticals Announces 69 Treated Patients 69 Colorectal Cancer Patients 69 ISTODAX ® 69 Preclinical Evaluation 69 Eluting Stent 69 PHASE III 69 Ischemic Stroke 69 Neoadjuvant Chemotherapy 69 Elagolix 69 Multiple Ascending Dose 69 Nicotine Vaccine 69 Treatment Regimen 69 pharmacokinetic PK study 69 Prophylactic Treatment 69 Initiates Clinical 69 RNAi Therapeutic 69 Phase IIIb 69 Oral Calcitonin 69 Receives Approvable Letter 69 PRN FDA Approves 69 Dendritic Cells 69 Beneficial Effects 69 Skeletal Muscle 69 Sirolimus Eluting 69 Treating Chronic 69 Mg Usa 69 Chronic Hepatitis B 69 Slows Progression 69 Phase 2a Study 69 Begins Dosing 69 Ozarelix 69 Oral Formulation 69 Therapeutic Vaccine 69 Vitro Activity 69 Achieves Primary Endpoint 69 Commences Phase 69 Zoledronic Acid 69 Diabetic Neuropathy 69 Anticancer Drug 69 Biomarker Study 69 Drug Eluting 69 Fondaparinux 69 Medoxomil 69 Eculizumab 69 Treatment Reduces 69 Multicenter Study 69 lexidronam injection 69 CYT# potent vascular disrupting 69 Chronic Sinusitis 69 J Am Acad 69 Initiates Clinical Trials 69 INSPIRE Trial Phase III 69 Epoetin Alfa 69 Novel Compound 69 Newly Diagnosed 69 Novel Mechanism 69 Inhalation Solution 69 Advanced Ovarian Cancer 69 Predict Risk 69 PNP inhibitor 69 Acute Attacks 69 Phase Ib clinical trials 69 Bosutinib 69 Migraine Drug 69 Soft Tissue Sarcoma 69 mGluR5 negative 69 Multicenter Randomized 69 Phase IIa Trial 69 Therapeutic Potential 69 Progenitor Cells 69 Immunomedics Announces 69 Sirolimus Eluting Stent 69 Hemodialysis Patients 69 Refractory Angina 69 Cell Lymphoma 69 Telaprevir VX 69 Sipuleucel T 69 Demonstrates Sustained 69 Kidney Transplant Recipients 69 Prognostic Significance 69 Neoadjuvant 69 Postmenopausal Osteoporosis 69 Treatment Naive 69 Remission Maintenance 69 Inflammatory Arthritis 69 huN# DM1 68 PKC# 68 pan HDAC inhibitor 68 Demonstrated Significant 68 Preclinical Models 68 Decitabine 68 Sangamo BioSciences Announces 68 BRIM2 68 IL# PE#QQR 68 Treating Heart Failure 68 ST Elevation Myocardial 68 Immunotherapeutic 68 Carotid Stenting 68 Clinical Study Shows 68 Tumor Growth 68 Chronic Heart Failure 68 Low Dose 68 Cell Transplants 68 Lowers Risk 68 Safety Tolerability 68 Blinatumomab 68 Receptor Antagonist 68 Left Ventricular Hypertrophy 68 Hepatitis C Patients 68 Androgen Deprivation Therapy 68 Epratuzumab 68 sunitinib Sutent ® 68 Advanced Solid Tumors 68 metastatic castration resistant 68 Monoclonal Antibody 68 Therapy Improves 68 Colorectal Adenomas 68 Adalimumab 68 Aliskiren 68 Successfully Treated 68 Shows Promise Against 68 Multiple Myeloma Patients 68 Receives Milestone Payment 68 Nymox NX 68 Oral Mucositis 68 Demonstrate Significant 68 Non Alcoholic Steatohepatitis 68 bone marrow reticulin deposition 68 Fulvestrant 68 Transdermal Patch 68 Acute Decompensated Heart Failure 68 Initiates Phase 2b 68 evaluating tivozanib 68 Desvenlafaxine Succinate 68 Phase Ib clinical 68 Significantly Improves 68 Advaxis Phase 68 Synta Announces 68 Pegylated 68 Osteoporosis Drug 68 EVIZON TM 68 Percutaneous Tibial Nerve Stimulation 68 Treatment Shows Promise 68 Expanded Indication 68 Inhalation Aerosol 68 Dose Response 68 Renal Cancer 68 Bortezomib 68 Multicenter 68 Teva Provides Update 68 TRANSFORMS 68 Lung Cancer Patients 68 Myelodysplastic Syndrome MDS 68 Epilepsy Drug 68 Intracranial Aneurysms 68 treat benign prostatic 68 Phase 1b clinical trials 68 Mycophenolate Mofetil 68 Cardiovascular Events 68 Drug Combo 68 Generic Version 68 PEGylated interferon beta 1a 68 Completes Patient Enrolment 68 J Am Coll 68 Unstable Angina 68 Systemic Sclerosis 68 Lupus Drug 68 Prospective Multicenter 68 Anticancer Drugs 68 Interferon beta 1a 68 Treatment Naïve Patients 68 transthyretin TTR mediated amyloidosis 68 CCX# B 68 Diffuse Large B 68 non nucleoside inhibitor 68 Atypical Hemolytic Uremic Syndrome 68 Antiangiogenic 68 CLINICAL TRIAL 68 5q MDS 68 Bone Metastases 68 Systemic Delivery 68 First Patient Treated 68 FDA Approves Drug 68 Immune Responses 68 AAG geldanamycin analog 68 Rotavirus Vaccine 68 Replacement Therapy 68 Peginterferon Alfa 2b 68 Mouse Models 68 TRIAL OF 68 FDA Clears 68 Tanespimycin 68 Ocrelizumab 68 Intravenous Formulation 68 Hepatitis B Vaccine 68 IIa trial 68 Pharmacokinetic 68 R Saizen R 68 Malignant Glioma 68 THAT ARE DIFFICULT TO 68 Recurrent Breast Cancer 68 Receives FDA Clearance 68 Significantly Reduced 68 Drug Fails 68 Ovarian Cancer Patients 68 Randomized Controlled Trials 68 Infarct 68 Interferon Gamma 68 Significantly Reduces 68 Golimumab 68 Vascular Disrupting Agent 68 Primary Hypercholesterolemia 68 Renal Artery 68 vapreotide acetate 68 Brain Metastases 68 SPRYCEL ® 68 Targeted Therapies 68 Inhibits 68 Omacetaxine 68 Osteoarthritis Patients 68 Antitumor activity 68 Induction Therapy 67 5 FU leucovorin 67 Less Invasive 67 Combo Therapy 67 Critically Ill Patients 67 Selective Cardiac Myosin 67 Adenoma 67 Relapsed Refractory Multiple Myeloma 67 Intravitreal 67 Cardiac Resynchronization 67 Confirms Efficacy 67 Proc Am Soc 67 Phase 2a trial 67 Stent Thrombosis 67 Commence Phase 67 Immunogenicity 67 Romiplostim 67 FUSILEV ® 67 Anticancer Compound 67 FDA Okays 67 Stem Cell Treatment 67 ERBITUX cetuximab 67 Ziprasidone 67 TNF Tumor Necrosis Factor 67 Fixed Dose 67 Anthracycline 67 dyskinesia PD LID 67 Follicular Lymphoma 67 Telik logo TELINTRA 67 Liver Tumors 67 HALTS 67 Randomized Trials 67 Partial Onset Seizures 67 Osteoporosis Treatment 67 Patient Outcomes 67 Zenvia Phase III 67 dextromethorphan quinidine 67 Efficacy Results 67 cell lymphoma CTCL 67 Cethromycin 67 Cannabinor 67 Inhaled Insulin 67 ORENCIA ® 67 Phospholipase A2 67 Tumor Progression 67 histone deacetylase HDAC inhibitor 67 Allogeneic 67 Non Responders 67 essential thrombocythemia ET 67 Myelofibrosis 67 J Shoulder Elbow 67 Prostate Cancer Treatment 67 Oral Presentation 67 Multicenter Phase 67 Melphalan 67 Gene Variant 67 Poster Presentations 67 Liposomal 67 Combination Clinical Trial 67 Efficacious 67 Localized Prostate Cancer 67 Peginterferon Alfa 2a 67 Myocardial Infarction Study 67 Orthostatic Hypotension 67 Cardiotoxicity 67 Enzyme Replacement Therapy 67 Venous Thromboembolism 67 PET FROM 67 Bone Mineral Density 67 Phase IIIb clinical 67 FEMALES SHOULD BE ADVISED 67 Antitumor 67 dose escalation clinical 67 cetuximab Erbitux R 67 CYPHER R Sirolimus Eluting 67 Pharmacodynamics 67 FUSILEV enhances 67 Radiofrequency Ablation 67 Attenuates 67 Recurrent Glioblastoma 67 Nucleoside 67 Oral Cladribine 67 Diabetic Macular Edema 67 Milestone Payment 67 CARDIOVASCULAR 67 Small Molecule 67 phase IIb clinical 67 Hematological Malignancies 67 pan histone deacetylase 67 GOUT 67 CHEAP ONLINE PHARMACY BEST 67 Reports Preclinical Data 67 THERAPEUTICS 67 Intravesical 67 PRTX 67 lead Aganocide compound 67 Tiotropium 67 Mg Uk 67 Lung Cancer Survival 67 Pemphigus Vulgaris 67 Diabetic Neuropathic Pain 67 Cypher Sirolimus 67 Advanced Pancreatic Cancer 67 interferon beta 1a infertility 67 Seasonal Allergic Rhinitis 67 Lung Cancers 67 Plaque Psoriasis 67 Eluting Coronary Stent System 67 Bladder Cancer 67 Peripheral Arterial 67 Rheumatoid Arthritis Drug 67 Newly Diagnosed Patients 67 trial evaluating PRX# 67 Phase 2a clinical 67 oral dual endothelin 67 Hepatitis C Genotype 67 Fracture Risk 67 Immunomodulatory 67 ATRA IV 67 Angiogenic 67 Surgical Treatment 67 Phase Ib II 67 Hypercholesterolemia 67 Beta Blocker 67 Adjunctive 67 allosteric modulator NAM 67 Aggressive Reduction 67 TMC# C# 67 Pafuramidine 67 Phase 1a clinical 67 diarrhea predominant irritable 67 Minimally Invasive Treatment 67 Anticancer Agent 67 Announces FDA Clearance 67 Demonstrates Potential 67 Ofatumumab 67 PEG IFN 67 Chronic Constipation 67 FDA Approves 67 Pharmacyclics Announces 67 Tocilizumab 67 Lung Cancer Drug 67 Receptor Antagonists 67 Artery Disease 67 Cerebril TM 67 ThermoDox R 67 Azacitidine 67 ritonavir boosted 67 Bosentan 67 FDA Clearance 67 J Clin 67 Receives Orphan Drug 67 Phase 1b trial 67 brand ciclesonide HFA 67 Gastric Cancer 67 Randomized Phase III 67 Naive Patients 67 Files Investigational 66 Gene Linked 66 QLT# 66 Fluorouracil 66 PEGINTRON TM 66 FOLFOX6 chemotherapy regimen 66 Potent Inhibitor 66 Intervention Effectiveness 66 Relapsed 66 Parkinson disease levodopa induced 66 Atypical Antipsychotic 66 huC# DM4 66 Multicenter Trial 66 Successfully Treats 66 Philadelphia Chromosome Positive 66 Androgen Receptor 66 Tumor Response 66 Taro Receives 66 Aneurysm Repair 66 Reperfusion Injury 66 phase IIa 66 Regenerative Cells 66 Patient Treated 66 Phase #b/#a clinical 66 TREATMENT OF 66 Acute Myocardial 66 Pivotal Phase II 66 Inflammatory Markers 66 Mimetics 66 Robotic Assisted 66 Bone Morphogenetic Protein 66 Schizophrenia Drug 66 Genes Predict 66 Arthritis Drug 66 Phase IIB 66 PROSTASCINT R 66 investigational humanized monoclonal antibody 66 ORLive Presents 66 Tumor Targeting 66 Sandostatin R 66 Orthop Surg 66 Dapagliflozin 66 Data Suggest 66 Hepatitis C Treatment 66 Bevacizumab 66 Left Ventricular 66 Malignancies 66 Aortic Stenosis 66 INCB# [003] 66 Inhaled Nitric Oxide 66 ODT metoclopramide HCl PEPCID 66 IS ASSOCIATED WITH 66 Acute Heart Failure 66 Total Knee Arthroplasty 66 Bazedoxifene 66 acute peripheral arterial 66 Natalizumab 66 Receives Fast Track 66 Endometrial Cancer 66 Degarelix 66 Virus Linked 66 Oral Insulin 66 Ischemic 66 Paclitaxel Carboplatin 66 Improve Outcomes 66 Reveals Positive 66 Abstract Number 66 Tesetaxel 66 Autoimmune Diseases 66 Methylnaltrexone 66 Cardiogenic Shock 66 investigational oral inhibitor 66 Vaccine Candidate 66 Capecitabine 66 Drug Prevents 66 Telbivudine 66 Novel Small Molecule 66 Enrolls First 66 Pneumococcal Vaccine 66 Heterozygous Familial Hypercholesterolemia 66 CUTTING THE 66 recurrent glioblastoma multiforme 66 5 fluorouracil leucovorin 66 Non Invasive 66 Antiviral Therapy 66 Drug Eluting Stents 66 Sustained Reduction 66 Treatment Naive HIV 66 Novel Compounds 66 ACTEMRA TM 66 Molecular Diagnostic Test 66 Traficet EN 66 Radioimmunotherapy 66 Immunosuppression 66 dual endothelin receptor antagonist 66 Carboplatin Paclitaxel 66 Deforolimus 66 Osteoporosis Drugs 66 Cognitive Impairment 66 RISKS UNCERTAINTIES AND ASSUMPTIONS 66 HuMax EGFr 66 PREVAIL 66 BARACLUDE ® 66 Nitazoxanide 66 RNAi Therapeutics 66 Bare Metal Stent 66 phase IIa clinical 66 Lenocta TM 66 Contrast Agents 66 Hematological Cancers 66 Generalized Anxiety Disorder 66 Long Term Outcomes 66 Randomised 66 Treat Anemia 66 Insulin Glargine 66 Temsirolimus 66 ACE Inhibitors 66 Emerging Therapies 66 Shows Statistically Significant 66 Rigel R# 66 Capsules CII 66 recurrent glioma 66 8mg/kg 66 Breast Cancer Recurrence 66 Carcinomas 66 Enzastaurin 66 Myeloid 66 metastatic malignant 66 Denufosol 66 Develop Novel 66 COLLABORATION WITH 66 atypical Hemolytic Uremic Syndrome 66 Adenoviral 66 Syncria R 66 Levels Linked 66 Fluvastatin 66 Smallpox Vaccine 66 Metastatic Pancreatic Cancer 66 STELARA TM 66 Bucindolol 66 Randomized Clinical Trials 66 Novolimus 66 Premature Infants 66 Oral Presentations 66 Paclitaxel Eluting 66 Drug Resistant 66 myelodysplastic myeloproliferative diseases 66 Nuvelo Announces 66 Diabetic Foot Ulcer 66 Antiplatelet 66 albiglutide 66 Psoriasis Drug 66 Patent Covering 66 Tesamorelin 66 registrational trial 66 Arterial Disease 66 See CONTRAINDICATIONS 66 Increased Risk 66 Reduces Mortality 66 Increased Mortality 66 Tipranavir 66 complement inhibitor eculizumab 66 polymerase inhibitor 66 Contrast Agent 66 Observational Study 66 Nat Clin Pract 66 Obese Patients 66 Second Pivotal Phase 66 Phase III PREGNANT PROCHIEVE 66 Human Monoclonal Antibody 66 hypertrichosis occurred 66 LENALIDOMIDE 66 CHEAP ONLINE PHARMACY LOW 66 phase IIb trial 66 severe oral mucositis 66 PHARMACEUTICALS INC 66 B Cell Malignancies 66 Nasdaq HALO 66 product platforms AZX# 66 novel VDA molecule 66 Double Blind Randomized 66 Schizophrenia Treatment 66 Randomized Placebo Controlled 66 Early Relapsing Multiple 66 Cardiol 66 Cancer Cachexia 66 Vitrasert R 66 MAGE A3 ASCI 66 TRANSDUR ® 66 Oral Anticoagulant 65 Cyclin Dependent 65 IIa clinical 65 Chronic Renal Failure 65 Cardiovascular Outcomes 65 PDUFA Date 65 Targeted Therapy 65 Certolizumab 65 Curr Opin 65 CYP#A# CYP#D# 65 NAVISTAR R 65 Acute Migraine 65 Luteinizing Hormone Releasing Hormone 65 Granulocyte Colony Stimulating Factor 65 sunitinib Sutent 65 Abstract Accepted 65 THERAPY FOR 65 Cyclophosphamide 65 Controlled Clinical Trial 65 Phase IIb trials 65 Pharmacokinetic Pharmacodynamic 65 Albuferon TM 65 Androgen Independent 65 Extended Release 65 SABCS 65 TNF Blockers 65 Prognostic Value 65 Occlusive Disease 65 Lamotrigine 65 TKB# 65 Prednisone Against Refractory 65 Post Operative 65 Shows Promise 65 Xenografts 65 Test Detects 65 ® lenalidomide 65 Initiates Dosing 65 Pralatrexate 65 NASH Huntington 65 virus HCV protease inhibitor 65 Receives SFDA Approval 65 Catheter Ablation 65 Blood Pressure Drug 65 Antifungal 65 Testosterone MDTS ® 65 Nilotinib 65 Study Shows Promise 65 Interferon Alpha 65 Secondary Hyperparathyroidism 65 davunetide intranasal AL 65 Genes Linked 65 TLK# 65 Systematic Review 65 Kamada AAT 65 Irinotecan 65 Bivalirudin 65 Eur J 65 PEGylated anti 65 Pancreatic Adenocarcinoma 65 Seliciclib CYC# 65 THE ORLANDO FLA. 65 ABLYNX 65 Vaginal Gel 65 evaluating mipomersen 65 Abiraterone Acetate 65 Epidermal Growth Factor Receptor 65 Clostridium difficile Infection 65 multicenter Phase 65 catheter occlusion 65 Left Ventricular Dysfunction 65 Hepatic Encephalopathy 65 Viral Suppression 65 ON TWITTER AND 65 registrational Phase 65 Prostate AdenoCarcinoma Treatment 65 Chronic Bronchitis 65 Circulating Tumor Cells 65 C1 Inhibitor 65 Topical Treatment 65 Endovascular Treatment 65 Peripheral Blood 65 Protease Inhibitors 65 Central Retinal Vein 65 prostate cancer mCRPC 65 TRANSDUR ™ 65 BCG refractory carcinoma 65 relapsing multiple sclerosis 65 MyVax R 65 Anti CD# Antibody 65 AVASTIN 65 mapatumumab 65 Zorbtive TM 65 lucinactant 65 Phase IIa trial 65 receptor tyrosine kinase inhibitor 65 Activator CK # 65 Gene Mutation 65 interferon gamma 1b 65 Cholesterol Drug 65 Serious Infections 65 Am J Respir 65 WE WILL CONTINUE TO 65 abacavir sulfate lamivudine 65 Stomach Cancer 65 ST Elevation Acute 65 Randomized Evaluation 65 induced macular edema 65 TM Drug Eluting 65 Breast Cancer Patients 65 methylnaltrexone bromide 65 LymphoStat B TM 65 samarium Sm 65 ALN HPN 65 Blood Pressure Lowering 65 Phase 2a 65 Laquinimod 65 Factor Receptor 65 Pulmonary Artery 65 ST Segment Elevation 65 Increases Risk 65 Ovitrelle R Serostim 65 Tolvaptan 65 TAXUS ATLAS 65 Myocardial Ischemia 65 Enrolling Patients 65 sorafenib Nexavar 65 Reduced Incidence 65 icatibant 65 refractory chronic lymphocytic 65 adalimumab Humira 65 Heart Transplant Recipients 65 intravesical infusion therapy 65 Renal Function 65 Ambrisentan